Product: Fosphenytoin

Captisol-enabled™ Fosphenytoin is an IV and IM compound specifically formulated for patients at risk for or to control status epilepticus seizures occurring during or following neurosurgery or neurologic trauma. Cerebyx (fosphenytoin) is currently indicated in these conditions, but requires refrigerated storage. Captisol-enabled™ Fosphenytoin holds potential for onsite dispensing in vials, syringes and pre-mixed bags in emergency rooms, intensive care units, first responder vehicles or aircraft, and serial seizures in long-term care facilities. The product has completed pivotal studies.

About Captisol®

Captisol is Ligand Pharmaceuticals’ patent-protected, chemically modified cyclodextrin that has a chemical structure that was specifically engineered to maximize administration safety while improving solubility, stability and bioavailability of active pharmaceutical ingredients (APIs).

Given the well-established contribution of Captisol to the stability and solubility of APIs, it has been an integral part of New Drug Approval submissions for a number of established global companies in the pharmaceutical industry. Captisol has enabled the development of life-saving medicines in a variety of therapy areas including antifungals, CNS disorders, cardiovascular, and oncology. Extensive preclinical and clinical safety studies have been performed relating to Captisol and indicate that it is safe when administered parenterally, orally and in other routes of administration, and that it does not exhibit toxicities commonly associated with other cyclodextrins. Ligand maintains a large safety database for Captisol within Type IV and V Drug Master Files submitted to the FDA that contain over 200 clinical and safety studies, which Ligand’s license partners can reference for their development efforts with new Captisol-enabled medicines. There are more than 45 Captisol-enabled products currently in development.

Captisol’s broad intellectual property estate includes issued patents in over 60 countries with a potential patent term to 2033.

 For more information, visit www.captisol.com.